ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Valeant And Watson Buy Into Generics

by Ann M. Thayer
May 30, 2011 | APPEARED IN VOLUME 89, ISSUE 22

Looking to spend its money after failing to take over Cephalon, Valeant Pharmaceuticals will acquire the specialty drug firm AB Sanitas for about $443 million in cash. Based in Kaunas, Lithuania, Sanitas sells branded generic drugs throughout Central and Eastern Europe. Valeant expects its sales to reach more than $140 million this year. Separately, Watson Pharmaceuticals has bought the generic drug maker Specifar Pharmaceuticals for $562 million. The Greek firm had 2010 sales of about $120 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment